GGG

GENOMED

No trades
See on Supercharts
Market capitalization
‪39.11 M‬PLN
‪991.50 K‬PLN
‪22.48 M‬PLN
Beta (1Y)
−0.55

About GENOMED

CEO
Anna Boguszewska-Chachulska
Website
Headquarters
Warsaw
Employees (FY)
45
Founded
2007
ISIN
PLGNOMD00024
FIGI
BBG001P21SH4
Genomed SA engages in the provision of medical diagnostic services. It offers DNA analysis and congenital diseases diagnostics based on DNA sequencing for scientific centers, biotechnological companies, and medical institutions. The company was founded by Andrzej Henryk Palucha, Anna Boguszewska-Chachulska, Marek Zagulski, and Iwona Wach on September 5, 2007 and is headquartered in Warsaw, Poland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GEN is 29.6 PLN — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NEWCONNECT exchange GENOMED stocks are traded under the ticker GEN.
GEN stock is 0% volatile and has beta coefficient of −0.55. Check out the list of the most volatile stocks — is GENOMED there?
Yes, you can track GENOMED financials in yearly and quarterly reports right on TradingView.
GEN stock hasn't changed in a week, the last month showed zero change in price, over the last year GENOMED has showed a 24.49% decrease.
GEN net income for the last quarter is ‪1.38 M‬ PLN, while the quarter before that showed ‪66.22 K‬ PLN of net income which accounts for ‪1.99 K‬% change. Track more GENOMED financial stats to get the full picture.
Today GENOMED has the market capitalization of ‪39.11 M‬, it has decreased by 0.68% over the last week.
GENOMED dividend yield was 0% in 2023, and payout ratio reached 0%. The year before the numbers were 0% and 0% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, GEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENOMED stock right from TradingView charts — choose your broker and connect to your account.
GEN reached its all-time high on Jun 15, 2021 with the price of 50.0 PLN, and its all-time low was 3.4 PLN and was reached on May 27, 2014.
See other stocks reaching their highest and lowest prices.
As of Apr 20, 2024, the company has 45.00 employees. See our rating of the largest employees — is GENOMED on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENOMED technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENOMED stock shows the sell signal. See more of GENOMED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENOMED EBITDA is ‪2.25 M‬ PLN, and current EBITDA margin is 10.00%. See more stats in GENOMED financial statements.